Sponsors / KNSA
KNSA

Kiniksa Pharmaceuticals International, plc

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationNCT04447469KNSAPhase 2, Phase 3Completed2021-11-12Actual
A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseNCT06531395KNSAPhase 2Terminated2025-03-06Actual
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387NCT07010159KNSAPhase 2, Phase 3Recruiting2027-12-31Estimated
Transition to KPL-387 Monotherapy Dosing & Administration StudyNCT07288216KNSAPhase 2Recruiting2027-12-31Estimated

Latest recorded trial changes